당뇨치료제
In order to develop a new diabetes treatment, technology partnership and joint research with the US pharmaceutical venture company Pharmzens and Baylor School of Medicine.
A Recombinant Human Insulin Analog
- - Production in invivo folding, effect of increasing profitability
- - Reducing production costs and improving production processes
- - Stable formulation under neutral pH conditions
- - No need to add toxic chemicals during formation
- - Persistent and high blood sugar-lowering effect
- - Securing in vitro and preclinical experimental results for effective blood sugar drop
- - US Patent Application (US Patent 62952742)
- - Oral hypoglycemic agent
Pharmzens
Glycemic Control Supplement
- VitaGlu™
- - Helps suppress postpartum blood sugar elevation and is necessary for normal immune function
- - Production in full at FDA-certified CGMP manufacturing facilities in the United States
- - Health functional food approved by the Ministry of Food and Drug Safety
Video